Leoni Mollie's Form 4 filing
Kura Oncology, Inc. (KURA) · filed Nov 14, 2025
- Accession no.
- 0001193125-25-283563
- Filed
- Nov 14, 2025
- Trade date
- Nov 13-14, 2025
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. Open-market sales total $173.1K. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Leoni MollieCIK 0002051106 | Officer (Chief Medical Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 13, 2025 | Common Stock | AGrant or awardAcquired | +82,500 | $0.00 | $0 | 240,939 | Direct | |
| Nov 14, 2025 | Common Stock | SSaleDisposed | −15,485 | $11.18 | −$173,122.3 | 225,454 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.